1-9 of 9
Daniel W. Bowles
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers

Available to Purchase
Jena D. French, Bryan R. Haugen, Francis P. Worden, Daniel W. Bowles, Andrew G. Gianoukakis, Bhavana Konda, Ramona Dadu, Eric J. Sherman, Shaylene McCue, Nathan R. Foster, Yuri E. Nikiforov, Ticiana D.J. Farias, Paul J. Norman, Lori J. Wirth
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (17): 3757–3767.
https://doi.org/10.1158/1078-0432.CCR-23-3417
Published: 03 September 2024
View articletitled, Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
Open the PDF for Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers in another window
Includes: Supplementary data
Journal Articles

A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma

Open Access
Glenn J. Hanna, Myung-Ju Ahn, Jameel Muzaffar, Bhumsuk Keam, Daniel W. Bowles, Deborah J. Wong, Alan L. Ho, Sung-Bae Kim, Francis Worden, Tak Yun, Xianzhang Meng, Jan M. Van Tornout, Maureen G. Conlan, Hyunseok Kang
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (22): 4555–4563.
https://doi.org/10.1158/1078-0432.CCR-23-1030
Published: 14 November 2023
View articletitled, A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma
Open the PDF for A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma in another window
Includes: Supplementary data
Journal Articles

Final Report of a Phase I Trial of Olaparib with Cetuximab and Radiation for Heavy Smoker Patients with Locally Advanced Head and Neck Cancer

Free
Sana D. Karam, Krishna Reddy, Patrick J. Blatchford, Tim Waxweiler, Alicia M. DeLouize, Ayman Oweida, Hilary Somerset, Carrie Marshall, Christian Young, Kurtis D. Davies, Madeleine Kane, Aik Choo Tan, Xiao Jing Wang, Antonio Jimeno, Dara L. Aisner, Daniel W. Bowles, David Raben
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (20): 4949–4959.
https://doi.org/10.1158/1078-0432.CCR-18-0467
Published: 15 October 2018
View articletitled, Final Report of a Phase I Trial of Olaparib with Cetuximab and Radiation for Heavy Smoker Patients with Locally Advanced Head and Neck Cancer
Open the PDF for Final Report of a Phase I Trial of Olaparib with Cetuximab and Radiation for Heavy Smoker Patients with Locally Advanced Head and Neck Cancer in another window
Includes: Supplementary data
Journal Articles

Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers

Free
Nikita Pozdeyev, Laurie M. Gay, Ethan S. Sokol, Ryan Hartmaier, Kelsi E. Deaver, Stephanie Davis, Jena D. French, Pierre Vanden Borre, Daniel V. LaBarbera, Aik-Choon Tan, Rebecca E. Schweppe, Lauren Fishbein, Jeffrey S. Ross, Bryan R. Haugen, Daniel W. Bowles
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (13): 3059–3068.
https://doi.org/10.1158/1078-0432.CCR-18-0373
Published: 01 July 2018
View articletitled, Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers
Open the PDF for Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers in another window
Includes: Supplementary data
Journal Articles

Salivary Gland Cancer Patient-Derived Xenografts Enable Characterization of Cancer Stem Cells and New Gene Events Associated with Tumor Progression

Free
Stephen B. Keysar, Justin R. Eagles, Bettina Miller, Brian C. Jackson, Farshad N. Chowdhury, Julie Reisinger, Tugs-Saikhan Chimed, Phuong N. Le, John J. Morton, Hilary L. Somerset, Marileila Varella-Garcia, Aik-Choon Tan, John I. Song, Daniel W. Bowles, Mary E. Reyland, Antonio Jimeno
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (12): 2935–2943.
https://doi.org/10.1158/1078-0432.CCR-17-3871
Published: 14 June 2018
View articletitled, Salivary Gland Cancer Patient-Derived Xenografts Enable Characterization of Cancer Stem Cells and New Gene Events Associated with Tumor Progression
Open the PDF for Salivary Gland Cancer Patient-Derived Xenografts Enable Characterization of Cancer Stem Cells and New Gene Events Associated with Tumor Progression in another window
Includes: Supplementary data
Journal Articles

Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations

Free
Kai Wang, Jeffery S. Russell, Jessica D. McDermott, Julia A. Elvin, Depinder Khaira, Adrienne Johnson, Timothy A. Jennings, Siraj M. Ali, Molly Murray, Carrie Marshall, Dwight S. Oldham, Donna Washburn, Stuart J. Wong, Juliann Chmielecki, Roman Yelensky, Doron Lipson, Vincent A. Miller, Philip J. Stephens, Hilary S. Serracino, Jeffrey S. Ross, Daniel W. Bowles
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (24): 6061–6068.
https://doi.org/10.1158/1078-0432.CCR-15-2568
Published: 15 December 2016
View articletitled, Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations
Open the PDF for Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations in another window
Includes: Supplementary data
Journal Articles

Phase I Dose-Escalation Trial of the Oral Investigational Hedgehog Signaling Pathway Inhibitor TAK-441 in Patients with Advanced Solid Tumors

Free
Jonathan Goldman, S. Gail Eckhardt, Mitesh J. Borad, Kelly K. Curtis, Manuel Hidalgo, Emiliano Calvo, David P. Ryan, Lori J. Wirth, Asit Parikh, James Partyka, Helene Faessel, Esha Gangolli, Sally Stewart, Lee S. Rosen, Daniel W. Bowles
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2015) 21 (5): 1002–1009.
https://doi.org/10.1158/1078-0432.CCR-14-1234
Published: 01 March 2015
View articletitled, Phase I Dose-Escalation Trial of the Oral Investigational Hedgehog Signaling Pathway Inhibitor TAK-441 in Patients with Advanced Solid Tumors
Open the PDF for Phase I Dose-Escalation Trial of the Oral Investigational Hedgehog Signaling Pathway Inhibitor TAK-441 in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Phase I Study of Oral Rigosertib (ON 01910.Na), a Dual Inhibitor of the PI3K and Plk1 Pathways, in Adult Patients with Advanced Solid Malignancies

Free
Daniel W. Bowles, Jennifer R. Diamond, Elaine T. Lam, Colin D. Weekes, David P. Astling, Ryan T. Anderson, Stephen Leong, Lia Gore, Marileila Varella-Garcia, Brian W. Vogler, Stephen B. Keysar, Elizabeth Freas, Dara L. Aisner, Chen Ren, Aik-Chook Tan, Francois Wilhelm, Manoj Maniar, S. Gail Eckhardt, Wells A. Messersmith, Antonio Jimeno
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (6): 1656–1665.
https://doi.org/10.1158/1078-0432.CCR-13-2506
Published: 13 March 2014
View articletitled, Phase I Study of Oral Rigosertib (ON 01910.Na), a Dual Inhibitor of the PI3K and Plk1 Pathways, in Adult Patients with Advanced Solid Malignancies
Open the PDF for Phase I Study of Oral Rigosertib (ON 01910.Na), a Dual Inhibitor of the PI3K and Plk1 Pathways, in Adult Patients with Advanced Solid Malignancies in another window
Includes: Supplementary data
Journal Articles

A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors

Free
David S. Hong, Daniel W. Bowles, Gerald S. Falchook, Wells A. Messersmith, Goldy C. George, Cindy L. O'Bryant, Alex C. H. Vo, Kevin Klucher, Roy S. Herbst, S. Gail Eckhardt, Scott Peterson, Diana F. Hausman, Razelle Kurzrock, Antonio Jimeno
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (15): 4173–4182.
https://doi.org/10.1158/1078-0432.CCR-12-0714
Published: 30 July 2012
View articletitled, A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors
Open the PDF for A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data